High-Throughput Screening to Identify Novel Compounds Affecting the Genome Editing Efficiency of CRISPR System
Open Access
Abstract
Genome editing is a promising therapeutic strategy for genetic disorders by modifying the genome precisely, especially the CRISPR/Cas9 system. However, a major limitation of CRISPR/Cas9 in gene therapy is the biosafety issues caused by off-target effects. Compounds that can modulate the genome editing efficiency of the CRISPR/Cas9 system, especially those reducing the off-target effects, are potentially useful pharmacological tools for improving the effectiveness and safety of genome editing. Here, we performed high-throughput screening in HEK 293FT cells to discover compounds that decrease or increase the genome editing efficiency of the CRISPR/Cas9 system from 9930 compounds. After two rounds of screening, we identified that CP-724714, a ErbB2 (HER2) tyrosine kinase inhibitor, decreased the CRISPR/Cas9 efficiency and reduced the off-target effects by suppressing the efficiency of CRISPR/Cas9, and was thus named a CRISPR decelerator (or inhibitor), while Clofarabine, a DNA synthesis inhibitor, increased the efficiency of CRISPR/Cas9, and was named a CRISPR accelerator. We further identified four compounds (Tranilast, Cerulenin, Rosolic acid and Resveratrol) that affected the efficiency of single-strand annealing (SSA) repair. Among them, Tranilast, Cerulenin and Rosolic acid are potential SSA decelerators, while Resveratrol is a potential SSA accelerator. These identified compounds may be useful in optimizing mammalian genetic manipulation techniques.Keywords
Funding Information
- Applied Basic Research Program of Shanxi Province (202203021212372, 82170523, 82170294)
- National Natural Science Foundation of China (202203021212372, 82170523, 82170294)
This publication has 70 references indexed in Scilit:
- CRISPR technology in human diseasesMedcomm, 2024
- Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCsBiomaterials, 2022
- A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9Cell, 2019
- SAA-Cas9: A tunable genome editing system with increased bio-safety and reduced off-target effectsJournal of Genetics and Genomics, 2019
- Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome EditingCell Reports, 2018
- Shortening the Half-Life of Cas9 Maintains Its Gene Editing Ability and Reduces Neuronal ToxicityCell Reports, 2018
- Finding the ‘Guilty’ Gene Variant of Sporadic Parkinson’s Disease Via CRISPR/Cas9Neuroscience Bulletin, 2016
- Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing SpecificityCell, 2013
- Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR/Cas9 SystemCell Reports, 2013
- One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome EngineeringCell, 2013